MDxHealth has appointed Michael Brawer as chief medical officer. Brawer is a urologist and former professor of urology and pathology. He most recently served as vice president of medical affairs for urology at Myriad Genetics, where he led all clinical aspects of development, education, and commercialization of the firm's prognostic prostate cancer assay. Previously, Brawer held senior leadership positions at GTx, Tokai Pharmaceuticals, and Threshold Pharmaceuticals. HE was also a practicing urologist and the director of the Northwest Prostate Institute for almost a decade, and held teaching positions in pathology and urology at the University of Washington and University of Arizona.